Locally Advanced Solid Tumor

Oncology
9
Pipeline Programs
7
Companies
8
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
6
3
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Tango Therapeutics
Tango TherapeuticsMA - Cambridge
2 programs
2
TNG462Phase 1/21 trial
TNG908Phase 1/21 trial
Active Trials
NCT05732831Recruiting225Est. Sep 2026
NCT05275478Active Not Recruiting192Est. Dec 2025
Ipsen
IpsenChina - Tianjin
1 program
1
IPN60300Phase 1/21 trial
Active Trials
NCT07213817Recruiting114Est. Oct 2028
Acepodia
AcepodiaCA - Alameda
2 programs
2
ACE1702Phase 11 trial
CyclophosphamidePhase 11 trial
Active Trials
NCT04319757CompletedEst. Jul 2024
NCT06415487RecruitingEst. Mar 2027
AN
Adlai NortyeNORTH BRUNSWICK, NJ
1 program
1
AN2025Phase 11 trial
Active Trials
NCT04975958CompletedEst. Jan 2025
Compass Therapeutics
1 program
1
CTX-471Phase 1
Sanofi
SanofiPARIS, France
1 program
1
MSC1936369BPhase 11 trial
Active Trials
NCT01390818Completed146Est. Apr 2015
ImmunityBio
ImmunityBioSAN DIEGO, CA
1 program
1
PD-L1 t-haNKPhase 11 trial
Active Trials
NCT04050709Active Not Recruiting16Est. Mar 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
IpsenIPN60300
Tango TherapeuticsTNG462
Tango TherapeuticsTNG908
AcepodiaCyclophosphamide
Adlai NortyeAN2025
AcepodiaACE1702
ImmunityBioPD-L1 t-haNK
SanofiMSC1936369B

Clinical Trials (8)

Total enrollment: 693 patients across 8 trials

NCT07213817IpsenIPN60300

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

Start: Dec 2025Est. completion: Oct 2028114 patients
Phase 1/2Recruiting
NCT05732831Tango TherapeuticsTNG462

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Start: May 2023Est. completion: Sep 2026225 patients
Phase 1/2Recruiting
NCT05275478Tango TherapeuticsTNG908

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Start: Mar 2022Est. completion: Dec 2025192 patients
Phase 1/2Active Not Recruiting
NCT06415487AcepodiaCyclophosphamide

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

Start: Aug 2024Est. completion: Mar 2027
Phase 1Recruiting
NCT04975958Adlai NortyeAN2025

Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

Start: Sep 2021Est. completion: Jan 2025
Phase 1Completed
NCT04319757AcepodiaACE1702

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

Start: Jun 2020Est. completion: Jul 2024
Phase 1Completed
NCT04050709ImmunityBioPD-L1 t-haNK

QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers

Start: Jul 2019Est. completion: Mar 202616 patients
Phase 1Active Not Recruiting
NCT01390818SanofiMSC1936369B

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Start: May 2011Est. completion: Apr 2015146 patients
Phase 1Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2m ago

Office Administrator

SystImmune
2m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
13m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
16m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
16m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 693 patients
7 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)